Tapentadol Prolonged Release

DRUG5 trials

Sponsors

Grünenthal GmbH

Conditions

Back PainCancerChronic PainLow Back PainNeuropathic PainNociceptive PainPain

Phase 2

A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain

CompletedNCT02151682

Grünenthal GmbHPain

Start: 2015-04-29End: 2018-10-15Updated: 2019-09-12

Phase 3

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability

TerminatedNCT00986258

Grünenthal GmbHChronic Pain, Low Back Pain, Neuropathic Pain +2

Start: 2009-10-30End: 2011-01-31Updated: 2019-01-09

Tapentadol in Chronic Malignant Tumour Related Pain

TerminatedNCT01264887

Grünenthal GmbHCancer, Chronic Pain, Pain

Start: 2011-03-31End: 2014-05-31Updated: 2019-11-04

Phase 4

Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin

CompletedNCT01352741

Grünenthal GmbHLow Back Pain, Neuropathic Pain

Start: 2011-03-31End: 2012-01-31Updated: 2019-10-28

Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.

CompletedNCT01838616

Grünenthal GmbHBack Pain, Low Back Pain, Neuropathic Pain

Start: 2013-04-30End: 2014-01-31Updated: 2016-02-24